Medicine
Treximet 500 mg/85 mg tablet
Treximet 500 mg/85 mg tablet is a prescription medicine containing Naproxen and Sumatriptan for oral use, marketed by Currax Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25°C (77°F), excursions permitted to 15°-30°C (59°-86°F). Do not…
Key facts
- Active ingredient (INN)
- Naproxen and Sumatriptan
- Brand
- Treximet
- Strength
- 500 mg/85 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 9 tablets
- Marketing authorisation holder
- Currax Pharmaceuticals
- Manufacturer
- Currax Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77°F), excursions permitted to 15°-30°C (59°-86°F). Do not repackage, dispense and store in original container with desiccant.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 25 April 2008
- Identifiers
- RxCUI 849450, 849452DailyMed set ID 42ddf376-8dc0-4236-be2a-0c6ae92ece04NDC 42847-850Application NDA021926
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 9 tablet, film coated in 1 bottle | 42847-850-09 | Currax Pharmaceuticals | 25 April 2008 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 15 April 2008 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Naproxen and Sumatriptan 500 mg/85 mg tablet.
Clinical summary
Naproxen and Sumatriptan is a fixed-dose combination of a nonsteroidal anti-inflammatory drug and a serotonin-1b and serotonin-1d receptor agonist indicated for the acute treatment of migraine, among other approved uses. MedsAcross supplies Naproxen and Sumatriptan for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Naproxen and SumatriptanFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Sumatriptan Succinate and Naproxen Sodium prescribing information (Cypress, Hawthorn, Macoven) · U.S. National Library of Medicine, DailyMed
Need Treximet 500 mg/85 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.